Download KKT-forskningsgruppene i de kliniske avdelingene: Årsrapport 2012

KKT-forskningsgruppene i de kliniske avdelingene: Årsrapport 2013
Forskningsgruppeleder:
Forskningsgruppe:
Kontaktadresse:
Forankringsavdeling:
Arne Kolstad
Immunterapi
Avd for Kreftbehandling, OUS Radiumhospitalet
Avd for Kreftbehandling
For klinikkovergripende forskningsgrupper: Er skriftlig avtale inngått? (kryss av)
Ja
Nei
x
Gruppemedlemmer : Legg ved liste hvis det har vært endringer etter okt 2013.
Gruppemøter: Hvor mange gruppemøter er avholdt i 2013? (fyll ut)
2 møter
Samarbeid:
Type forskning i gruppen (kryss av)
Avdelinger representert i gruppen (fyll ut)
Fagområder representert i gruppen (fyll ut)
Profesjoner representert i gruppen (kryss
av)
Prosjektsamarbeid nasjonalt (oppgi
institusjon(er))
Prosjektsamarbeid internasjonalt (oppgi
land og institusjon(er))
Basal
x Klinisk
x Translasjon
(kan fylles ut av administrasjonen)
x
Leger
X
Helsefag
Realister
x
(Siv.)ing.
Annet
OUS, Universitetssykehuset Nord-Norge,
Bioteknologisenteret UiO
 Center for Cancer Immunotherapy (CCIT),
Herlev University Hospital
 Netherlands Cancer Institute (NKI),
Amsterdam
 University College London, UCL Cancer
Institute
 Institute of Molecular Immunology,
Helmholtz Zentrum München
 AdaptImmune Ltd, Oxford
 Stanford University, USA
 Vanderbilt University, Tennessee, USA
 Fred Hutchinson Cancer Institute, USA
 Karolinska Institutet, Sverige
 Minnesota University USA
 Mont Sinai School of Medicine, NY, USA
Pågående forskningsprosjekter i gruppen (fyll ut eller legg ved liste)
Prosjektleder
Prosjektnavn
Startdato/
måned
evt ekstern(e)
finansieringskilde(r)
Tildelt sum
1
Kalle malmberg
2014
Integrative profiling of
human NK cell repertoires /
Selective expansion of
educated NK cells for
cancer therapy
NFR,
kreftföreningen,
HSØ
7000k/år
Johanna Olweus
Cancer-targeted T cell
receptors – the next
generation
immunotherapeutic drugs
CD20-specific T cells in
immunotherapy of leukaemia
and lymphoma
Lymvac-1 cancer vaccine in
malignant lymphoma
2010/6
Helse Sør-øst
900.000/år
2009
NFR
1.100k/år
2007/12
2013/9
2012/12
Roche
Genterapimidler
Nordic
Nanovector
KKT
Lytix BioPharma
AS
Genterapimidler
1000k
Postdoc
Fullfinansiering
Johanna Olweus
Arne Kolstad
Arne Kolstad
Betalutin anti-CD37
radioimmunotherpy in
malignant lymphoma
Pål F. Brunsvig
LTX-315 clinical trial
melanoma
DC005 clinical trial in Prostate
cancer
Ultimovacs clinical trial NSCLC
2009/09
2012/12
Ultimovacs AS
Fullfinansiering
Targovax clinical trial
pancreatic cancer
Patient-derived T cell
receptors targeting cancer
2012/12
Targovax AS
Fullfinansiering
2013/01
Helse Sør Øst
Postdoc
stipend
Phase III trial of DC-based
vaccine against brain cancer
Identify and characterize
therapy-resistant tumour
cells in B-cell lymphoma
Assessment of aberrant
signaling pathways in B-cell
lymphoma – prognostic and
therapeutic potential
New diagnostic markers and
targets for therapeutic
intervention in
B-cell lymphoma
2013/09
Kreftforeningen
2013/01
Kreftforeningen
776k/år
2014
Helse Sør-Øst
900k / år
2014
NFR
2000k / år
Svein Dueland
Pål F. Brunsvig
Svein Dueland
Jon Amund Kyte
Iver Langmoen
Erlend Smeland/
June Myklebust
Erlend Smeland/
June Myklebust
Erlend Smeland/
June Myklebust
Fullfinansiering
Fullfinansiering
Publikasjoner: legg ved gruppens publikasjonsliste for 2013 se nederst
Dr grader avlagt siste år: (fyll ut)
2
Kandidatens navn
Olav E. Yri
Hovedveileder
Harald Holte, Erlend Smeland
Dato/måned
4/10-2013
Patentsøknader, Disclosure of invention (DOFI), lisens-/opsjonsavtaler, bedriftsetablering
(fyll ut)
Avtaleinnehavers navn
Johanna Olweus
Karl-Johan Malmberg
Tiltak og tittel
1.A novel technology platform for epitope
discovery
2.Novel peptide targets in lymphoma and
leukemia
Selective and Controlled Expansion of Educated
NK Cells for Cancer Therapy
Dato/måned
Desember
2012
September
2012
Publikasjoner 2013
Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A,
Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J,
Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt
LM, Gascoyne RD, Rimsza LM. Determining cell-of-origin subtypes of diffuse large
B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue.
Blood. 2014 Jan 7. [Epub ahead of print] PubMed PMID: 24398326.
Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O,
Olweus J, Gregers TF. Invariant chain as a vehicle to load antigenic peptides on
human MHC class I for cytotoxic T-cell activation. Eur J Immunol. 2013 Dec 2.
doi: 10.1002/eji.201343671. [Epub ahead of print] PubMed PMID: 24293164.
Taraldsrud E, Fevang B, Aukrust P, Beiske KH, Fløisand Y, Frøland S, Rollag H,
Olweus J. Common variable immunodeficiency revisited: normal generation of
naturally occurring dendritic cells that respond to toll-like receptors 7 and 9.
Clin Exp Immunol. 2013 Nov 18. doi: 10.1111/cei.12239. [Epub ahead of print]
PubMed PMID: 24237110.
3
Kumari S, Wälchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN,
Olweus J. Alloreactive cytotoxic T cells provide means to decipher the
immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc
Natl Acad Sci U S A. 2014 Jan 7;111(1):403-8. doi: 10.1073/pnas.1306549111. Epub
2013 Dec 16. PubMed PMID: 24344295.
Behnan J, Isakson P, Joel M, Cilio C, Langmoen IA, Vik-Mo EO, Badn W.
Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor
progression. Stem Cells. 2013 Dec 3. doi: 10.1002/stem.1614. [Epub ahead of
print] PubMed PMID: 24302539.
Murrell W, Palmero E, Bianco J, Stangeland B, Joel M, Paulson L, Thiede B,
Grieg Z, Ramsnes I, Skjellegrind HK, Nygård S, Brandal P, Sandberg C, Vik-Mo E,
Palmero S, Langmoen IA. Expansion of multipotent stem cells from the adult human
brain. PLoS One. 2013 Aug 14;8(8):e71334. doi: 10.1371/journal.pone.0071334.
eCollection 2013. PubMed PMID: 23967194; PubMed Central PMCID: PMC3743777.
Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W,
Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA.
Comparison of glioma stem cells to neural stem cells from the adult human brain
identifies dysregulated Wnt- signaling and a fingerprint associated with clinical
outcome. Exp Cell Res. 2013 Aug 15;319(14):2230-43. doi:
10.1016/j.yexcr.2013.06.004. Epub 2013 Jun 18. PubMed PMID: 23791939.
Joel M, Sandberg CJ, Boulland JL, Vik-Mo EO, Langmoen IA, Glover JC.
Inhibition of tumor formation and redirected differentiation of glioblastoma
4
cells in a xenotypic embryonic environment. Dev Dyn. 2013 Sep;242(9):1078-93.
doi: 10.1002/dvdy.24001. Epub 2013 Jul 29. PubMed PMID: 23780720.
Berg-Johnsen J, Helseth E, Langmoen IA. Cerebral Revascularization for Skull
Base Tumors. World Neurosurg. 2013 Mar 26. pii: S1878-8750(13)00546-9. doi:
10.1016/j.wneu.2013.03.052. [Epub ahead of print] PubMed PMID: 23541748.
Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody
JD. Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future
Oncol. 2013 Oct;9(10):1549-71. doi: 10.2217/fon.13.113. PubMed PMID: 24106904.
Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES,
Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA. Hierarchy in somatic
mutations arising during genomic evolution and progression of follicular
lymphoma. Blood. 2013 Feb 28;121(9):1604-11. doi: 10.1182/blood-2012-09-457283.
Epub 2013 Jan 7. PubMed PMID: 23297126; PubMed Central PMCID: PMC3587323.
Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K,
Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K,
Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam
AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma
Study Group. Bortezomib consolidation after autologous stem cell transplantation
in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013
Apr 24. PubMed PMID: 23616624; PubMed Central PMCID: PMC3674665.
Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T,
5
Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I,
Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L,
Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG). Impact
of malignant stem cell burden on therapy outcome in newly diagnosed chronic
myeloid leukemia patients. Leukemia. 2013 Jul;27(7):1520-6. doi:
10.1038/leu.2013.19. Epub 2013 Jan 18. PubMed PMID: 23328954.
Os A, Bürgler S, Ribes AP, Funderud A, Wang D, Thompson KM, Tjønnfjord GE,
Bogen B, Munthe LA. Chronic lymphocytic leukemia cells are activated and
proliferate in response to specific T helper cells. Cell Rep. 2013 Aug
15;4(3):566-77. doi: 10.1016/j.celrep.2013.07.011. Epub 2013 Aug 8. PubMed PMID:
23933259.
del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R,
González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F,
Aptsiauri N. Immune escape of cancer cells with beta2-microglobulin loss over the
course of metastatic melanoma. Int J Cancer. 2014 Jan 1;134(1):102-13. doi:
10.1002/ijc.28338. Epub 2013 Jul 16. PubMed PMID: 23784959.
Bengnér M, Béziat V, Ernerudh J, Nilsson BO, Löfgren S, Wikby A, Malmberg KJ,
Strindhall J. Independent skewing of the T cell and NK cell compartments
associated with cytomegalovirus infection suggests division of labor between
innate and adaptive immunity. Age (Dordr). 2013 Sep 25. [Epub ahead of print]
PubMed PMID: 24065293.
Béziat V, Traherne JA, Liu LL, Jayaraman J, Enqvist M, Larsson S, Trowsdale J,
Malmberg KJ. Influence of KIR gene copy number on natural killer cell education.
6
Blood. 2013 Jun 6;121(23):4703-7. doi: 10.1182/blood-2012-10-461442. Epub 2013
May 1. PubMed PMID: 23637128; PubMed Central PMCID: PMC3674669.
Sternberg-Simon M, Brodin P, Pickman Y, Onfelt B, Kärre K, Malmberg KJ,
Höglund P, Mehr R. Natural killer cell inhibitory receptor expression in humans
and mice: a closer look. Front Immunol. 2013 Mar 26;4:65. doi:
10.3389/fimmu.2013.00065. eCollection 2013. PubMed PMID: 23532016; PubMed Central
PMCID: PMC3607804.
Béziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Björklund AT, Retière
C, Sverremark-Ekström E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale
J, Michaëlsson J, Ljunggren HG, Malmberg KJ. NK cell responses to cytomegalovirus
infection lead to stable imprints in the human KIR repertoire and involve
activating KIRs. Blood. 2013 Apr 4;121(14):2678-88. doi:
10.1182/blood-2012-10-459545. Epub 2013 Jan 16. PubMed PMID: 23325834; PubMed
Central PMCID: PMC3617633.
Vanherberghen B, Olofsson PE, Forslund E, Sternberg-Simon M, Khorshidi MA,
Pacouret S, Guldevall K, Enqvist M, Malmberg KJ, Mehr R, Önfelt B. Classification
of human natural killer cells based on migration behavior and cytotoxic response.
Blood. 2013 Feb 21;121(8):1326-34. doi: 10.1182/blood-2012-06-439851. Epub 2013
Jan 3. PubMed PMID: 23287857.
Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim
S, Bruland OS, Hall KS, Tierens A, Delabie J. Malignant phyllodes tumor and acute
megakaryoblastic leukemia sharing a common clonal origin. Case Rep Hematol.
2013;2013:934781. doi: 10.1155/2013/934781. Epub 2013 Dec 17. PubMed PMID:
7
24455338.
Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR.
The clinical impact of mean vessel size and solidity in breast carcinoma
patients. PLoS One. 2013 Oct 11;8(10):e75954. doi: 10.1371/journal.pone.0075954.
PubMed PMID: 24146798; PubMed Central PMCID: PMC3795733.
Haldorsen K, Bruland O, Appel S, Bolstad AI. Reply to 'comment on no
association of primary Sjögren's syndrome with Fcγ receptor gene variants'. Genes
Immun. 2013 Dec;14(8):532. doi: 10.1038/gene.2013.51. Epub 2013 Oct 10. PubMed
PMID: 24108103.
Sapkota D, Costea DE, Ibrahim SO, Johannessen AC, Bruland O. S100A14 interacts
with S100A16 and regulates its expression in human cancer cells. PLoS One. 2013
Sep 27;8(9):e76058. doi: 10.1371/journal.pone.0076058. PubMed PMID: 24086685;
PubMed Central PMCID: PMC3785438.
Rusten E, Rødal J, Bruland Ø, Malinen E. Biologic targets identified from
dynamic 18FDG-PET and implications for image-guided therapy. Acta Oncol. 2013
Oct;52(7):1378-83. doi: 10.3109/0284186X.2013.813071. Epub 2013 Aug 28. PubMed
PMID: 23981046.
Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A. De novo Huntington
disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology.
2013 Sep 17;81(12):1099-100. doi: 10.1212/WNL.0b013e3182a4a4af. Epub 2013 Aug 14.
PubMed PMID: 23946314; PubMed Central PMCID: PMC3795589.
8
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki
A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D,
James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M,
Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas
J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223
and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul
18;369(3):213-23. doi: 10.1056/NEJMoa1213755. PubMed PMID: 23863050.
Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S,
Johannesen TB, Fosså SD. Incidence and mortality of second sarcomas - a
population-based study. Eur J Cancer. 2013 Oct;49(15):3292-302. doi:
10.1016/j.ejca.2013.05.017. Epub 2013 Jun 17. PubMed PMID: 23787025.
Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE,
Trovik CS, Bruland OS. Patterns of local recurrence and dose fractionation of
adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity
and trunk wall. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):949-55. doi:
10.1016/j.ijrobp.2013.04.015. Epub 2013 May 29. PubMed PMID: 23725998.
Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L,
Seierstad T. Multimodal functional imaging for early response assessment in GIST
patients treated with imatinib. Acta Oncol. 2014 Jan;53(1):143-8. doi:
10.3109/0284186X.2013.798428. Epub 2013 May 28. PubMed PMID: 23710697.
Berland S, Appelbäck M, Bruland O, Beygo J, Buiting K, Mackay DJ, Karen
Temple I, Houge G. Evidence for anticipation in Beckwith-Wiedemann syndrome. Eur
J Hum Genet. 2013 Dec;21(12):1344-8. doi: 10.1038/ejhg.2013.71. Epub 2013 Apr 10.
9
PubMed PMID: 23572028; PubMed Central PMCID: PMC3831082.
Haldorsen K, Appel S, Le Hellard S, Bruland O, Brun JG, Omdal R,
Kristjansdottir G, Theander E, Fernandes CP, Kvarnström M, Eriksson P, Rönnblom
L, Herlenius MW, Nordmark G, Jonsson R, Bolstad AI. No association of primary
Sjögren's syndrome with Fcγ receptor gene variants. Genes Immun. 2013
Jun;14(4):234-7. doi: 10.1038/gene.2013.12. Epub 2013 Apr 4. PubMed PMID:
23552400.
Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J.
Effect of vitamin D supplementation and ultraviolet B exposure on serum
25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover
clinical trial. Br J Dermatol. 2013 Aug;169(2):434-40. doi: 10.1111/bjd.12349.
PubMed PMID: 23551243.
Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J. Targeted
alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude
mice. Curr Radiopharm. 2013 Jun 6;6(2):106-16. PubMed PMID: 23551111.
Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J. Comparing high LET
227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3
xenografts. Curr Radiopharm. 2013 Jun 6;6(2):78-86. PubMed PMID: 23551110.
Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H,
Seierstad T. Intermittent and continuous imatinib in a human GIST xenograft model
carrying KIT exon 17 resistance mutation D816H. Acta Oncol. 2013
May;52(4):776-82. doi: 10.3109/0284186X.2013.770920. Epub 2013 Mar 13. PubMed
10
PMID: 23480638; PubMed Central PMCID: PMC3622233.
Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E.
Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue
sarcomas. Acta Oncol. 2013 Aug;52(6):1160-7. doi: 10.3109/0284186X.2012.728713.
Epub 2012 Dec 3. PubMed PMID: 23198721.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B,
Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M,
Bolstad B, Bruland ØS. Two-year survival follow-up of the randomized,
double-blind, placebo-controlled phase II study of radium-223 chloride in
patients with castration-resistant prostate cancer and bone metastases. Clin
Genitourin Cancer. 2013 Mar;11(1):20-6. doi: 10.1016/j.clgc.2012.07.002. Epub
2012 Sep 26. PubMed PMID: 23021204.
Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal
metastases. Cancer Treat Rev. 2013 Feb;39(1):18-26. doi:
10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24. Review. PubMed PMID: 22534284.
Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB,
Holte H. High dose chemotherapy with autologous stem cell transplantation for
patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leuk
Lymphoma. 2014 Jan 16. [Epub ahead of print] PubMed PMID: 24432894.
Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H,
Delabie J, Smeland EB, Lind GE. Colorectal cancer DNA methylation marker panel
validated with high performance in Non-Hodgkin lymphoma. Epigenetics. 2013 Dec
11
20;9(3). [Epub ahead of print] PubMed PMID: 24362313.
Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH,
Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB. Whole-genome integrative
analysis reveals expression signatures predicting transformation in follicular
lymphoma. Blood. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24357726.
Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J,
Smeland EB, Lind GE. Identification of highly methylated genes across various
types of B-cell non-hodgkin lymphoma. PLoS One. 2013 Nov 19;8(11):e79602. doi:
10.1371/journal.pone.0079602. PubMed PMID: 24260260; PubMed Central PMCID:
PMC3834187.
Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo
A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier
B. A randomized study of interferon α-2b versus no treatment as consolidation
after high dose therapy and autologous stem cell transplantation for patients
with relapsed lymphoma. Oncologist. 2013;18(11):1189. doi:
10.1634/theoncologist.2013-0223. Epub 2013 Oct 8. PubMed PMID: 24105750; PubMed
Central PMCID: PMC3825302.
Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H.
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with
poor patient outcome. Eur J Haematol. 2013 Oct;91(4):332-8. doi:
10.1111/ejh.12171. Epub 2013 Aug 17. PubMed PMID: 23859481.
Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg A,
12
Hjalmarsson E, Holte H, Ostenstad B, Brown PD, Smeland EB, Kimby E. Higher World
Health Organization grades of follicular lymphoma correlate with better outcome
in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk
Lymphoma. 2013 Jun 14. [Epub ahead of print] PubMed PMID: 23662992.
Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H,
Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R,
Wickmann L, Schellong G. Treatment of children and adolescents with Hodgkin
lymphoma without radiotherapy for patients in complete remission after
chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol.
2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18.
PubMed PMID: 23509321.
Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A.
Enhancement characteristics of retroperitoneal lymphomatous lymph nodes. Acta
Radiol. 2013 Apr 1;54(3):333-9. doi: 10.1258/ar.2012.120679. Epub 2013 Feb 27.
PubMed PMID: 23446747.
Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H.
Influence of polymorphisms in genes encoding immunoregulatory proteins and
metabolizing enzymes on susceptibility and outcome in patients with diffuse large
B-cell lymphoma treated with rituximab. Leuk Lymphoma. 2013 Oct;54(10):2205-14.
doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2. PubMed PMID: 23391141.
Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C,
Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg
E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.
13
Dose-densified chemoimmunotherapy followed by systemic central nervous system
prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3
lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol.
2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17. PubMed
PMID: 23247661.
Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S,
Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA. Malignant
melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen.
2013 Oct 29;133(20):2154-9. doi: 10.4045/tidsskr.12.1416. Review. English,
Norwegian. PubMed PMID: 24172628.
Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM,
Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K,
Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against
autologous cancer stem cells with mRNA-transfected dendritic cells in patients
with glioblastoma. Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi:
10.1007/s00262-013-1453-3. Epub 2013 Jul 2. PubMed PMID: 23817721; PubMed Central
PMCID: PMC3755221.
Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay
G, Schadendorf D, Cantarini M, Spencer S, Middleton MR. Selumetinib plus
dacarbazine versus placebo plus dacarbazine as first-line treatment for
BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet
Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun
2. PubMed PMID: 23735514.
14
Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I,
Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in
patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. doi:
10.1016/j.ejca.2013.01.013. Epub 2013 Feb 21. PubMed PMID: 23433846.
Hagness M, Foss A, Egge TS, Dueland S. Patterns of Recurrence After Liver
Transplantation for Nonresectable Liver Metastases from Colorectal Cancer. Ann
Surg Oncol. 2013 Dec 27. [Epub ahead of print] PubMed PMID: 24370906.
Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM,
Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S. Liver
transplantation for nonresectable liver metastases from colorectal cancer. Ann
Surg. 2013 May;257(5):800-6. doi: 10.1097/SLA.0b013e3182823957. PubMed PMID:
23360920.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S,
Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek
H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive
and prognostic factors for treatment and survival in 305 patients with advanced
gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann
Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.
PubMed PMID: 22967994.
Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H,
Lauritzsen GF. Multimodal treatment with ALL-like chemotherapy, Auto-SCT and
radiotherapy for lymphoblastic lymphoma. Acta Oncol. 2013 Nov 18. [Epub ahead of
print] PubMed PMID: 24237392.
15
Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V,
Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S.
High-dose therapy with autologous stem cell support for lymphoma--from
experimental to standard treatment. Tidsskr Nor Laegeforen. 2013 Sep
3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. English, Norwegian. PubMed PMID:
24005713.
Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH. High dose cytarabine
with rituximab is not enough in first-line treatment of mantle cell lymphoma with
high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell
Lymphoma 5 trial. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print] PubMed PMID:
23876100.
Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman
J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. High PD-1
expression and suppressed cytokine signaling distinguish T cells infiltrating
follicular lymphoma tumors from peripheral T cells. Blood. 2013 Feb
21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7. PubMed
PMID: 23297127; PubMed Central PMCID: PMC3578953.
Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A,
Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new
anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res.
2013 Jan;33(1):85-95. PubMed PMID: 23267131.
16
17